Author + information
- Received October 5, 2015
- Revision received January 19, 2016
- Accepted January 20, 2016
- Published online March 9, 2016.
- Philipp Blanke, MDa,∗ (, )
- Christopher Naoum, MBBSa,
- Danny Dvir, MDa,
- Vinayak Bapat, MDb,
- Kevin Ong, MDa,
- David Muller, MBBSc,
- Anson Cheung, MDa,
- Jian Ye, MDa,
- James K. Min, MDd,
- Nicolo Piazza, MDe,
- Pascal Theriault-Lauzier, BSce,
- John Webb, MDa and
- Jonathon Leipsic, MDa
- aSt. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada
- bGuy’s and St. Thomas’ Hospital, London, United Kingdom
- cSt. Vincent’s Hospital, Sydney, Australia
- dNew York-Presbyterian Hospital and the Weill Cornell Medical College, New York, NY
- eMcGill University Health Centre, Montreal, QC, Canada
- ↵∗Reprint requests and correspondence:
Dr. Philipp Blanke, Centre for Heart Valve Innovation–St Paul’s Hospital & University of British Columbia, 1081 Burrard Street, Vancouver, Canada V6Z 1Y6.
- LVOT obstruction
- transcatheter mitral valve implantation
- transcatheter mitral valve replacement
Outflow tract obstruction is a feared and potentially lethal complication of transcatheter mitral valve replacement (TMVR), mitral valve-in-valve (ViV), and valve-in-ring (ViR) procedures as well as implantation of transcatheter heart valves in calcific mitral valve disease. These procedures ultimately lead to elongation of the outflow tract into the left ventricle, whereas the pre-existing “native” left ventricular outflow tract (LVOT) confined by the most basal septum and the intervalvular fibrosa remains unchanged (Figure 1). The newly created elongation of the outflow tract is confined posteriorly by the deflected anterior mitral valve leaflet in TMVR (Figures 1 and 2⇓), ViR, and calcific mitral valve procedures or by the deflected bioprosthetic leaflets and transcatheter heart valve struts in ViV procedures. To better discriminate from the native LVOT, we propose to refer to the newly created elongation as the “neo-LVOT” (1). Although risk factors for narrow neo-LVOT dimensions can be both device- and anatomy-related (Figure 3), we propose to perform a patient-specific assessment by means of computed tomography (CT)-based, virtual, stereolithographic device implantation. This requires segmentation of the native mitral annulus (2), the bioprosthetic sewing ring, or the annuloplasty ring, with subsequent definition of the annular plane and the annular trajectory by means of the least squares plane method to serve as anatomical landmarks for the subsequent device simulation (Figure 4) (1). With integrated device contours, the neo-LVOT can be segmented by means of a centerline technique to finally generate an orthogonal cross-sectional plane for planimetric “neo-LVOT” assessment (Figure 5). Here, we illustrate the concept of the neo-LVOT as well as the simulation and segmentation techniques essential to neo-LVOT prediction using cardiac CT (Figure 6).
Transcatheter valve implantation for native mitral valve disease and for failed surgical mitral valve replacement or repair elongate the outflow tract into the left ventricle, referred to as neo-LVOT. Pre-procedural CT-based device simulation may aid in identifying patients at an increased anatomical risk for small neo-LVOT dimensions and ultimately obstruction of the outflow tract.
Drs. Blanke and Leipsic provide core lab services to Edwards Lifesciences, Tendyne Holdings, and Neovasc; and serve as consultants to Edwards Lifesciences, Neovasc, and Circle Imaging. Drs. Webb, Dvir, Ye, and Cheung are consultants for Edwards. Dr. Piazza is a consultant for Medtronic.
- Received October 5, 2015.
- Revision received January 19, 2016.
- Accepted January 20, 2016.
- American College of Cardiology Foundation
- Blanke P.,
- Naoum C.,
- Webb J.,
- et al.
- Blanke P.,
- Dvir D.,
- Cheung A.,
- et al.